Cureline Inc is categorized under Commercial Biotechnical Research in South San Francisco, CA and active since 2003.
Cureline Inc was established in 2003, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Olga Potapova at the company’s headquarters by writing to 290 Utah Avenue 300, South San Francisco, California CA 94080 or by phoning (650) 875-6400. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Cureline Inc |
| Contact Person: | Olga Potapova |
| Address: | 290 Utah Avenue 300, South San Francisco, California 94080 |
| Phone Number: | (650) 875-6400 |
| Website Address: | cureline.com |
| Annual Revenue (USD): | $500.000 to $999.999 |
| Founded: | 2003 |
| Location Type: | Headquarters |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Cureline Inc was started in 2003 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact Olga Potapova for inquiries that concern Cureline Inc by calling the company number (650) 875-6400, as your correspondence is most welcome. Additionally, the physical location of the headquarters of Cureline Inc can be found at the coordinates 37.647023,-122.395098 as well as the street address 290 Utah Avenue 300 in South San Francisco, California 94080.
For its online presence, you may visit Cureline Inc’s website at cureline.com and engage with its social media outlets through on Twitter and on Facebook.